Search Results for: SRC

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
FASLG Fas ligand
  • Caspase activation via Death Receptors in the presence of ligand
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • Interleukin-4 and Interleukin-13 signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • FOXO-mediated transcription of cell death genes
  • TNFs bind their physiological receptors
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
FBP2 fructose-bisphosphatase 2
  • Gluconeogenesis
FBXO5 F-box protein 5
  • SCF-beta-TrCP mediated degradation of Emi1
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Mitotic Metaphase/Anaphase Transition
  • G1/S-Specific Transcription
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FHIT fragile histidine triad diadenosine triphosphatase
  • Adenosine monotungstate
  • Ado-P-Ch2-P-Ps-Ado
  • Small cell lung cancer
  • Non-small cell lung cancer
FLNA filamin A
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
  • Periventricular nodular heterotopia (PVNH)
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
FLT3 fms related receptor tyrosine kinase 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • FLT3 mutants bind TKIs
  • STAT5 activation downstream of FLT3 ITD mutants
  • KW2449-resistant FLT3 mutants
  • semaxanib-resistant FLT3 mutants
  • crenolanib-resistant FLT3 mutants
  • gilteritinib-resistant FLT3 mutants
  • lestaurtinib-resistant FLT3 mutants
  • midostaurin-resistant FLT3 mutants
  • pexidartinib-resistant FLT3 mutants
  • ponatinib-resistant FLT3 mutants
  • quizartinib-resistant FLT3 mutants
  • sorafenib-resistant FLT3 mutants
  • sunitinib-resistant FLT3 mutants
  • tandutinib-resistant FLT3 mutants
  • linifanib-resistant FLT3 mutants
  • tamatinib-resistant FLT3 mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Negative regulation of FLT3
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling through SRC family kinases
  • FLT3 signaling by CBL mutants
  • Sorafenib
  • Sunitinib
  • XL999
  • Tandutinib
  • Linifanib
  • Lestaurtinib
  • Midostaurin
  • Ponatinib
  • Nintedanib
  • Pacritinib
  • Tivozanib
  • Fostamatinib
  • Gilteritinib
  • Brigatinib
  • Fedratinib
  • Amuvatinib
  • Quizartinib
  • Pexidartinib
  • Pralsetinib
  • Acute myeloid leukemia (AML)
FMR1 fragile X messenger ribonucleoprotein 1
  • Premature ovarian failure
  • Fragile X Syndrome, including: Fragile X Syndrome (FXS); Fragile X tremor/ataxia syndrome (FXTAS)
FOXO1 forkhead box O1
  • AKT phosphorylates targets in the nucleus
  • Regulation of gene expression in beta cells
  • AKT-mediated inactivation of FOXO1A
  • Constitutive Signaling by AKT1 E17K in Cancer
  • MAPK6/MAPK4 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of localization of FOXO transcription factors
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of cell death genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • FOXO-mediated transcription of cell cycle genes
  • FOXO-mediated transcription of cell cycle genes
  • Alveolar rhabdomyosarcoma
FRS2 fibroblast growth factor receptor substrate 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Signaling by ALK
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Signaling by ALK fusions and activated point mutants
FYB1 FYN binding protein 1
  • Generation of second messenger molecules
  • Generation of second messenger molecules
  • Signal regulatory protein family interactions
FZR1 fizzy and cell division cycle 20 related 1
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of Emi1
  • Senescence-Associated Secretory Phenotype (SASP)
  • Assembly of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Transcriptional Regulation by VENTX
  • Aberrant regulation of mitotic exit in cancer due to RB1 defects
  • Antigen processing: Ubiquitination & Proteasome degradation
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
GAB2 GRB2 associated binding protein 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
GAB3 GRB2 associated binding protein 3
  • Signaling by CSF1 (M-CSF) in myeloid cells
GALNT12 polypeptide N-acetylgalactosaminyltransferase 12
  • Defective GALNT12 causes CRCS1
  • O-linked glycosylation of mucins
GFAP glial fibrillary acidic protein
  • Nuclear signaling by ERBB4
  • Chaperone Mediated Autophagy
  • Alexander disease
GIT1 GIT ArfGAP 1
  • Ephrin signaling
  • Ephrin signaling
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOQ GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • Activation of RAC1 downstream of NMDARs
GJA1 gap junction protein alpha 1
  • Oligomerization of connexins into connexons
  • Transport of connexins along the secretory pathway
  • Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
  • Gap junction assembly
  • Gap junction assembly
  • Gap junction degradation
  • Regulation of gap junction activity
  • Regulation of gap junction activity
  • Formation of annular gap junctions
  • RHOQ GTPase cycle
  • RHOJ GTPase cycle
  • SARS-CoV-2 targets PDZ proteins in cell-cell junction
  • Mechanical load activates signaling by PIEZO1 and integrins in osteocytes
  • Carvedilol
  • Deafness, autosomal recessive
  • Oculodentodigital dysplasia
  • Syndactyly
GJB1 gap junction protein beta 1
  • Oligomerization of connexins into connexons
  • Oligomerization of connexins into connexons
  • Transport of connexins along the secretory pathway
  • Gap junction assembly
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy

Page 22 out of 32 pages